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Abstract. Bmi1 is overexpressed in gastrointestinal cancers, 
including colorectal cancer (CRC); however, its role as a 
non-invasive biomarker in CRC has not been established. The 
aim of this study was to compare the plasma Bmi1 mRNA 
levels prior to and following curative resection of the primary 
tumor in CRC patients and to determine their association with 
the clinicopathological parameters. The plasma Bmi1 mRNA 
level was measured by quantitative polymerase chain reaction 
and expressed as cycle threshold value. There was no significant 
difference between the overall pre- and postoperative plasma 
Bmi1 mRNA level (31.73±2.63 vs. 31.93±2.88, respectively; 
P=0.614) in 45 CRC patients. However, when grouped into 
non-metastatic and metastatic CRC patients, the postopera-
tive Bmi1 transcript level was found to be significantly lower 
compared to the preoperative level in patients with non-meta-
static CRC (32.13±2.677 31.44±2.764, respectively; P=0.041), 
whereas there was a trend towards a higher postoperative 
Bmi1 transcript level compared to the preoperative level in 
the metastatic counterpart (30.85±3.916 vs. 33.27±0.718, 
respectively; P=0.164). Furthermore, when the patients were 
categorized into two groups according to their plasma Bmi1 
postoperative vs. preoperative level status, we observed that 
patients without a reduction in the postoperative plasma Bmi1 
mRNA levels exhibited a significantly higher rate of distant 
metastasis following primary resection (P=0.017) and a 
significantly worse prognosis regarding disease-free survival 
(P=0.016) when compared to the reduced postoperative plasma 
Bmi1 level counterparts. In conclusion, plasma Bmi1 mRNA 
levels may serve as a non-invasive biomarker for monitoring 
occult metastasis and predicting the development of distant 
metastasis.
Introduction
Colorectal cancer (CRC) is the third most commonly 
diagnosed cancer in males and the second in females, with 
>1.2 million new cancer cases and 608,700 deaths estimated 
to have occurred in 2008 (1). Recent advances in therapeutic 
strategies and surgical techniques have significantly improved 
the prognosis of CRC patients with primary disease; however, 
metastasis is a major concern for CRC patients and physicians. 
Thirty‑five percent of CRC patients have metastatic tumors 
at the time of diagnosis and 33-50% of the patients without 
metastases will progress to stage IV during the course of their 
disease (1,2). Hence, it is necessary to develop prominent 
biomarkers for detecting the presence of occult metastasis, as 
well as for predicting the development of future metastasis, 
which may provide a useful reference for the therapeutic 
management of CRC patients.
Potential stem cell marker, Bmi1, is a member of the 
polycomb-repressive complex 1, with a key role in gene 
silencing through chromatin modifications (3,4). In addition 
to the proposed role for Bmi1 as a key regulator of cell growth 
control/senescence mechanisms, accumulating evidence 
supports the role of Bmi1 in tumorigenesis. Bmi1 is overex-
pressed in a variety of human cancers and its overexpression 
was found to be correlated with tumor progression in CRC (5-7) 
and other gastrointestinal cancers, including esophageal squa-
mous cell carcinoma (8,9), pancreatic cancer (10) and gastric 
cancer (11), indicating its functional and prognostic role in 
gastrointestinal cancer patients. The Bmi1 autoantibody in 
the serum has also been suggested as a minimally invasive 
biomarker for the prognosis of nasopharyngeal (12), esopha-
geal squamous cell (8) and cervical carcinoma (13). More 
importantly, circulating Bmi1 mRNA has been detected in the 
plasma and was correlated with poor prognosis of advanced 
breast (14) and uterine cervical cancer patients (15). Those 
studies demonstrated the potential of Bmi1 as a non-invasive 
surrogate marker for a variety of cancer patients; however, 
such an application in CRC has not yet been investigated.
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In this study, the clinical significance of plasma Bmi1 
mRNA in CRC patients was investigated. The pre- and post-
operative plasma Bmi1 mRNA levels in CRC patients were 
determined by quantitative polymerase chain reaction (PCR) 
and correlated with the clinicopathological parameters, in 
order to determine whether monitoring of plasma Bmi1 in CRC 
patients is predictive of the development of distant metastasis.
Materials and methods
Patients and plasma samples. Blood samples were collected 
from 45 patients who underwent surgical resection of primary 
CRC during their follow-up at the Department of Surgery, 
Queen Mary Hospital, The University of Hong Kong, between 
2009 and 2013. Among these 45 patients, who presented with 
no evidence of distant metastasis at the time of the primary 
resection, 6 developed distant metastasis within 3 years, 
whereas the remaining patients were recurrence-free at the 
last follow-up visit to our clinic. The eligibility criteria for 
this study included pre- and postoperative plasma sample 
availability for quantitative PCR. Blood was anticoagulated 
by EDTA and centrifuged at 1,500 g for 10 min. The plasma 
was collected, divided into aliquots and snap-frozen at ‑80˚C 
until use.
This study was approved by the Institutional Review Board 
of our hospital and the patients provided written informed 
consent prior to inclusion.
RNA isolation, reverse transcription and quantitative PCR. 
RNA was isolated from 250 µl of plasma sample using 
the mirVana™ miRNA isolation kit (Life Technologies, 
Carlsbad, CA, USA), according to the manufacturer's instruc-
tions. For the synthesis of first‑strand cDNA, 8 µl RNA was 
reversed transcribed using PrimeScript™ RT Master mix 
(Takara Bio, Inc., Shiga, Japan) in accordance with the manu-
facturer's instructions. Quantitative PCR was performed in a 
final volume of 15 µl containing 1.5 µl RT transcript, 0.2 µM 
of each primer, 1X ROX reference dye and 7.5 µl of FastStart 
Universal SYBR-Green Master (ROX) (Roche Applied Science, 
Indianapolis, IN, USA). The Bmi1 forward and reverse primer 
sequences (5'-3') were ATCCCCACCTGATGTGTG and 
AAAGCCCTGGAACTAATTTG, respectively. Quantitative 
PCR was performed using the ABI 7900HT Fast Real-Time 
PCR system (Applied Biosystems, Foster City, CA, USA) at 
95˚C for 10 min, followed by 40 cycles at 95˚C for 15 sec and at 
56˚C for 1 min.
Statistical analysis. The plasma Bmi1 mRNA level was 
expressed as the cycle threshold (Ct) detected by quantitative 
PCR using the same threshold value of fluorescent signal 
intensity. The difference in plasma Bmi1 mRNA level between 
the two different groups was evaluated by the Student's t-test, 
whereas the difference between the pre- and postoperative 
blood levels in the same patient was evaluated by the paired 
t-test. The differences in recurrence rates among different 
groups of CRC patients were evaluated by the Fisher's 
exact test. The disease-free survival was analyzed using the 
Kaplan-Meier product limit method and the log-rank test. All 
the statistical analyses were performed with SigmaPlot soft-
ware, version 10.0 (Systat Software Inc., San Jose, CA, USA). 
P<0.05 was considered to indicate a statistically significant 
difference.
Results
Correlation of pre‑ and postoperative plasma Bmi1 mRNA 
levels with clinicopathological parameters. We first compared 
the plasma Bmi1 transcript level prior to and following 
surgical resection of primary colorectal tumor in 45 patients. 
As shown in Fig. 1, the pre- and postoperative Bmi1 tran-
script levels (expressed as mean Ct ± standard deviation, 
i.e., the higher the Ct, the lower the transcript level) were 
31.73±2.63 and 31.93±2.88, respectively, without a statistically 
significant difference between the two levels (P=0.614). We 
further compared the pre- and postoperative Bmi1 transcript 
levels in patients with different clinicopathological param-
eters (Table I). There were no significant changes in pre‑ and 
postoperative plasma Bmi1 transcript levels in CRC patients 
of different age, gender, lymph node status and TNM stage. 
However, the changes were significantly different between 
patients with metastatic and non-metastatic CRC. In the 
39 non-metastatic CRC patients, the postoperative Bmi1 
transcript level was significantly lower compared to the 
preoperative level (32.13±2.677 vs. 31.44±2.764, respectively; 
P=0.041). Furthermore, in the 6 CRC patients who devel-
oped metastasis, there was a trend for higher postoperative 
Bmi1 transcript level compared to the preoperative level 
(30.85±3.916 vs. 33.27±0.718, respectively; P=0.164). These 
results suggested that an increase in the postoperative Bmi1 
level correlated with the development of metastasis in CRC 
patients.
Due to sampling limitations, the postoperative blood plasma 
specimens were obtained from CRC patients at different time 
points following surgery (range, 0.5-25 months; median, 
5 months). To determine whether the length of time post-opera-
tion affects the plasma Bmi1 levels, we analyzed the association 
between the length of time post-operation and the difference 
between post- and preoperative plasma Bmi1 levels in CRC 
patients. Our results demonstrated that there was no significant 
correlation (r=-0.0116, P=0.945), suggesting that the length of 
time post-operation does not affect the results obtained.
Figure 1. Plasma Bmi1 transcript level prior to and following surgical resec-
tion of primary colorectal cancer in 45 patients. There was no significant 
difference (P=0.614) between the pre- (31.73±2.63) and postoperative 
(31.93±2.88) Bmi1 transcript levels (expressed as mean cycle threshold 
(Ct) ± standard deviation).
MOLECULAR AND CLINICAL ONCOLOGY  2:  817-820 819
Association of higher postoperative plasma Bmi1 mRNA with 
the development of distant metastasis. We next categorized 
the 45 patients into two groups according to their plasma Bmi1 
post- vs. preoperative level status (Table II). Of the 45 patients, 
29 exhibited a reduced postoperative Bmi1 level compared 
to the preoperative level, whereas 16 displayed increased or 
unchanged Bmi1 level following resection of the primary 
tumor. Of the 16 patients who exhibited no reduction in Bmi1 
level, 5 developed metastasis within 36 months post-operation. 
By contrast, only 1 of the 29 patients exhibiting lower post-
operative Bmi1 level developed metastasis, suggesting that 
patients with reduced postoperative Bmi1 levels were less 
likely to develop metastasis (P=0.017).
Finally, the prognostic significance of the changes in the 
post- vs. preoperative Bmi1 level in CRC patients was asessed 
(Fig. 2). The patients with a reduced postoperative Bmi1 
level (n=29) had a significantly better prognosis (P=0.016) 
for disease-free survival when compared to their increased 
postoperative Bmi1 level counterparts (n=16), further demon-
strating the correlation of changes in pre- and postoperative 
Bmi1 levels with the development of metastasis.
Our results suggested that reduced plasma Bmi1 transcript 
levels following resection of the primary tumor was a good 
prognostic factor for CRC patients, whereas patients with an 
increased Bmi1 level were more likely to develop postoperative 
metastasis. Therefore, monitoring the changes in the plasma 
Bmi1 level is a potential prognostic biomarker for the optimal 
management of CRC patients following curative resection of 
the primary tumor.
Discussion
Circulating Bmi1 mRNA prior to any treatment has been 
suggested as a surrogate marker of poor prognosis in patients 
with breast (14) and uterine cervical cancer (15). In our model, 
we observed that preoperative circulating Bmi1 mRNA did 
not correlate with any clinical parameters of CRC patients 
(data not shown), which may be explained by the relatively 
small number of patients recruited in this study. However, we 
demonstrated the significance of monitoring the changes in 
plasma Bmi1 transcript levels prior to and following surgical 
resection of the primary tumor in CRC patients, suggesting 
that monitoring the changes in circulating Bmi1 mRNA levels 
may be a more accurate prognostic biomarker in CRC patients.
Table I. Clinicopathological correlation of plasma Bmi1 
mRNA levels in colorectal cancer patients.
Clinico-  Plasma Bmi1 mRNA level
pathological No. of pre- vs. postoperarive
characteristics casesa (mean Ct ± SD) P-value
Age (years)
  <65 12 29.82±1.76 vs. 30.07±2.48 0.753
  ≥65 24 30.36±2.22 vs. 30.18±2.97 0.718
Gender
  Male 22 30.33±2.01 vs. 30.04±3.04 0.657
  Female 14 29.96±2.21 vs. 30.29±2.42 0.471
Tumor size
(cm)
  <5 15 30.48±2.32 vs. 29.99±3.20 0.523
  ≥5 9 30.18±2.16 vs. 30.49±2.70 0.589
Lymph node
metastasis
  Absent 17 30.04±2.14 vs. 30.57±2.34 0.224
  Present 15 30.45±2.27 vs. 29.77±3.49 0.439
TNM stage
  I-II 15 30.68±1.76 vs. 30.90±2.14 0.524
  III-IV 12 30.14±2.39 vs. 29.31±3.76 0.457
Distant
metastasis
  Absent 32 31.44±2.76 vs. 32.13±2.68 0.041
  Present 6 33.27±0.72 vs. 30.85±3.92 0.164
aThe total number of cases is <45 due to incomplete information. Ct, 
cycle threshold; SD, standard deviation.
Figure 2. Prognostic significance of changes in post‑ vs. preoperative Bmi1 
levels in colorectal cancer patients. Patients with a decreased postoperative 
plasma Bmi1 level (n=29) had a significantly better prognosis (P=0.016) for 
disease-free survival when compared to those with increased plasma postop-
erative Bmi1 levels (n=16).
Table II. Plasma Bmi1 mRNA level changes following cura-
tive resection of the primary tumor predict development of 
metastasis.
 Plasma Bmi1 mRNA level
 ---------------------------------------------------------------------------------------------
 Post- >preoperative Post- <preoperative
Metastatic 5 1
Non-metastatic 11 28
 Fisher's exact test: P=0.017
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Plasma Bmi1 mRNA levels in cancer patients were 
found to be significantly higher compared to those in normal 
subjects (14,15), suggesting that the increased circulating Bmi1 
mRNA may originate from the primary tumor and surgical 
resection of the primary tumor should bring down the levels 
of such transcripts. Of note, our study did not demonstrate 
such an effect. We found no significant difference between 
the overall pre- and postoperative plasma Bmi1 levels in CRC 
patients. Therefore, we hypothesized that a subset of CRC 
patients whose Bmi1 levels remained high following primary 
tumor resection accounted for such findings and we considered 
that those patients may be at higher risk of developing metas-
tasis, since high Bmi1 levels have been associated with cancer 
metastasis (15-18). To test our hypothesis, we divided the CRC 
patients into non-metastatic and metastatic and found that the 
postoperative circulating Bmi1 mRNA level in non-metastatic 
patients decreased to a mean value of 0.6-fold of the preop-
erative level, confirming that resection of the primary tumor 
removes the source of circulating Bmi1 mRNA. However, 
metastatic patients exhibited a mean of 5-fold induction in their 
circulating Bmi1 level postoperatively, which is most likely the 
result of dissemination of CRC tumor cells that accounted for 
the development of metastasis.
In the second part of our analysis, we found that monitoring 
the changes of plasma Bmi1 mRNA prior to and following 
curative resection was prognostic for the development of future 
metastasis, suggesting that circulating plasma Bmi1 mRNA 
may be used as a non-invasive biomarker for predicting and 
monitoring occult metastasis in CRC patients. We consider 
this finding to be useful for physicians in the postoperative 
treatment of CRC patients, such as applying a more aggressive 
dosage of adjuvant therapy to patients exhibiting no reduction 
of circulating Bmi1 mRNA after having their primary tumors 
removed.
Bmi1 mRNA and protein overexpression were previ-
ously demonstrated in CRC tumor (5,7) and were positively 
correlated with tumor stage, invasion and metastasis (6), as 
well as with poor disease-free and overall survival (6,19), 
suggesting that Bmi1 is a promising prognostic biomarker in 
CRC patients. To the best of our knowledge, this study was the 
first to further demonstrate that the changes in plasma Bmi1 
mRNA level prior to and following resection of the primary 
tumor was prognostic for the development of metastasis, 
indicating the potential of circulating Bmi1 mRNA levels as a 
non-invasive, convenient and relatively cost-effective surrogate 
biomarker for the management of postoperative CRC patients 
and possibly patients with other types of cancer in which Bmi1 
is also overexpressed.
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